Startseite Kongressberichte & Archiv Archiv 2018 Myeloid Diseases Myeloid Diseases News from Poster Sessions

Myeloid Diseases News from Poster Sessions

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). First Author: Courtney Denton Dinardo, The University of Texas MD Anderson Cancer Center, Houston, TX

Conclusions:mIDH inhibitor + AZA regimens were generally well tolerated in pts with ND-AML. Most AEs were grade 1-2 GI events and ENA-related indirect bilirubin elevations due to off-target UGT1A1 inhibition. Response rates are encouraging. Phase 1b enrollment completed in late 2017; updated data for all 23 IVO and 6 ENA pts will be presented, as well as longitudinal changes in mIDH variant allele frequencies. Enrollment continues in the phase 2 portion of this study (ENA + AZA) and the phase 3 AGILE study of IVO + AZA (NCT03173248). Clinical trial information: NCT02677922

J Clin Oncol 36, 2018 (suppl; abstr 7042)